Provectus Biopharmaceuticals Announces Decision to Not Undertake Reverse Split of Outstanding and Authorized Equities in 2022; Expects to Seek Same Stockholder Approval Again in 2023
12 déc. 2022 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company’s Board of Directors (Board) has decided to not undertake the reverse stock split and...
Cytotoxic Drugs and HPAPI Manufacturing Market Analysis Report 2022: New Research on 1 of the Most Powerful and Dynamic Sectors of the Pharmaceutical Industry - Industry Trends and Forecasts to 2035
07 déc. 2022 08h38 HE
|
Research and Markets
Dublin, Dec. 07, 2022 (GLOBE NEWSWIRE) -- The "Cytotoxic Drugs and HPAPI Manufacturing Market by Type of Product, Company Size, Scale of Operation, Type of Molecule, Type of Highly Potent Finished...
Synthetic Small Molecule API Market Report 2022: High Demand for Generic Drugs Bolsters Sector
01 déc. 2022 07h38 HE
|
Research and Markets
Dublin, Dec. 01, 2022 (GLOBE NEWSWIRE) -- The "Synthetic Small Molecule API Market Share, Size, Trends, Industry Analysis Report, By Application; By Manufacturer; By Region; Segment Forecast,...
Provectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10® and Keytruda® for First-Line Stage III Melanoma at Melanoma Bridge 2022
01 déc. 2022 07h00 HE
|
Provectus Biopharmaceuticals Inc.
50% CR and 83% ORR by RECIST 1.1 criteriaRapid CRs achieved within 15 to 27 weeksMedian PFS not reached during 2-year treatment interval; 83% PFS rate100% OS rate for CRs; ongoing after 18 to 36...
Recombinant Proteins Market Report 2022:Rising Government Funding and Increasing R&D Expenditure in Pharmaceutical and Biotechnology Companies Boosts Sector
30 nov. 2022 05h29 HE
|
Research and Markets
Dublin, Nov. 30, 2022 (GLOBE NEWSWIRE) -- The "Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery &...
Provectus Biopharmaceuticals Announces Acceptance of Small Molecule Cancer Immunotherapy PV-10® Stage III Melanoma Abstract at Melanoma Bridge 2022
10 nov. 2022 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company’s ongoing, multi-cohort, Phase 1b/2 study of the combination therapy of cancer...
Insights on the Rare Diseases Treatment Global Market to 2028 - Players Include AbbVie, F. Hoffmann-La Roche, Bayer, Novartis and Merck
10 nov. 2022 07h03 HE
|
Research and Markets
Dublin, Nov. 10, 2022 (GLOBE NEWSWIRE) -- The "Global Rare Diseases Treatment Market Size, Share & Industry Trends Analysis Report By Distribution Channel (Specialty Pharmacy, Hospital Pharmacy,...
Global Synthetic Small Molecule API Market Report 2022: Featuring Merck, Viatris, Cipla, Teva, Sun Pharmaceuticals & More
07 nov. 2022 04h48 HE
|
Research and Markets
Dublin, Nov. 07, 2022 (GLOBE NEWSWIRE) -- The "Global Synthetic Small Molecule API Market Size, Share & Industry Trends Analysis Report by Manufacturer, Application, Regional Outlook and...
Provectus Biopharmaceuticals Announces World Health Organization Selection of “Rose Bengal Sodium” as International Nonproprietary Name for Active Pharmaceutical Ingredient
02 nov. 2022 09h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO) has...
Pharma R&D Outsourcing Global Market Report 2022: Increasing Collaboration and partnership among CROs and Stakeholders Drives Growth
27 oct. 2022 08h13 HE
|
Research and Markets
Dublin, Oct. 27, 2022 (GLOBE NEWSWIRE) -- The "Pharma R&D Outsourcing Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.In a world of...